Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: An evidence-based assessment

Journal of Occupational and Environmental Medicine

Volumn 48, Issue 9, 2006, Pages 937-947

  Borak, Jonathan ^a,b,d   Woolf, Steven H ^c   Fields, Cheryl A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Jonathan Borak and Company   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM;

BERYLLIOSIS; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; HUMAN; LYMPHOCYTE PROLIFERATION; MEDICAL LITERATURE; PREVALENCE; PUBLICATION; RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SENSITIZATION;

EID: 33748691187     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000232548.03207.9f     Document Type: Article

References (93)

1. Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. Baltimore: Williams & Wilkins; 1996.
2. Williamson ML, Koch R, Azen C, Chang C. Correlates of intelligence test results in treated phenylketonuric children. Pediatrics. 1981;68:161-167.
3. Azen CG, Koch R, Friedman EG, et al. Intellectual development in 12-year-old children treated for phenylketonuria. Am J Dis Child. 1991;145:35-39.
4. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
5. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166:38-43.
6. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the US Preventive Services Task Force. Ann Intern Med. 2004;140:740-753.
7. Sackett DL, Hayes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little Brown; 1991.
8. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(suppl 3):21-35.
9. Gray JAM. Evidence-Based Healthcare. How to Make Health Policy and Management Decisions. Edinburgh: Churchill Livingstone; 2001.
10. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. New York, Geneva: World Health Organization; 1968.
11. Barratt A, Irwig L, Glasziou P, et al. Users' guides to the medical literature. XVII: how to use guidelines and recommendations about screening. JAMA. 1999;281:2029-2034.
12. Schroder FH. Detection of prostate cancer: the impact of the European Randomized Study of screening for prostate cancer (ERSPC). Can J Urol. 2005;12:92-93.
13. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 1995;333:1401-1405.
14. Winchester DP, Jeske JM, Goldschmidt RA. The diagnosis and management of ductal carcinoma in-situ of the breast. CA Cancer J Clin. 2000;50:184-200.
15. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546-1554.
16. Frame PS. Routine screening for lung cancer? Maybe someday, but not yet. JAMA. 2000;284:1980-1983.
17. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-162.
18. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J. 1978;40:636-643.
19. Last JM. A Dictionary of Epidemiology. New York: Oxford University Press; 2001.
20. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol. 1946;28:197-211.
21. Pneumoconiosis: Beryllium, Bauxite Fumes, Compensation (Sixth Saranac Symposium). New York: Paul Hoeber; 1950.
22. Hardy HL. United States, Beryllium Case Registry (1952-1966): review of its methods and utility. J Occup Med. 1967;9:271-276.
23. Sprince NL. Beryllium disease. In: Merchant JA, ed. Occupational Respiratory Diseases (NIOSH Publication No. 86-102). Washington, DC: US Department of Health and Human Services (NIOSH); 1986:385-399.
24. Kazemi H. Beryllium disease. In: Last JM, ed. Maxcy-Roseneau Preventive Medicine and Public Health. New York: Appleton-Century-Crofts; 1980:663-667.
25. Seeler AO. Treatment of chronic beryllium poisoning. AMA Arch Ind Health. 1959;19:82-86.
26. Maier LA. Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg. 2001;16:514-520.
27. Deodhar SD, Barna B, Van Ordstrand HS. A study of the immunologic aspects of chronic berylliosis. Chest. 1973;63:309-313.
28. Epstein PE, Dauber JH, Rossman MD, Daniele RP. Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonitis. Ann Intern Med. 1982;97:213-216.
29. Williams WJ, Williams WR. Value of beryllium lymphocyte transformation tests in chronic beryllium disease and in potentially exposed workers. Thorax. 1983;38:41-44.
30. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium: a test for chronic beryllium disease. Ann Intern Med. 1988;108:687-693.
31. Deubner D, Kelsh M, Shum M, Maier L, Kent M, Lau E. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl Occup Environ Hyg. 2001;16:579-592.
32. Yassin A, Yebesi F, Tingle R. Occupational exposure to crystalline silica dust in the United States. Environ Health Perspect. 2005;113:255-260.
33. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989;139:1479-1486.
34. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med. 1989;31:603-608.
35. Rossman MD, Edelman JF. Chronic beryllium and hard-metal lung disease. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. New York: McGraw-Hill; 1998:893-899.
36. Mroz MM, Balkissoon R, Newman LS. Beryllium. In: Bingham E, Cohrssen B, Powell CH, eds. Patty's Toxicology, Volume 2, Toxicological Issues Related to Metals/Neurotoxicology and Radiation/Metals and Metal Compounds. New York: John Wiley & Sons; 2000:177-219.
37. Culver DA, Dweik RA. Chronic beryllium disease. Clin Pulm Med. 2003;10:72-79.
38. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2005;171:54-60.
39. Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993;148:985-991.
40. Barna BP, Culver DA, Yen-Lieberman B, Dweik RA, Thomassen MJ. Clinical application of beryllium lymphocyte proliferation testing. Clin Diagn Lab Immunol. 2003;10:990-994.
41. Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect. 1996;104(suppl 5):937-943.
42. Cullen MR. Screening for chronic beryllium disease: one hurdle down, two to go. Am J Respir Crit Care Med. 2005;171:3-4.
43. Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 2005;26:543-549.
44. Williams WJ. United Kingdom beryllium registry: mortality and autopsy study. Environ Health Perspect Suppl. 1996;104(suppl 5):949-951.
45. Newman LS, Maier LA, Nemery B. Interstitial lung disorders due to beyllium and cobalt. In: Schwarz MI, King TE, eds. Interstitial Lung Disease. Hamilton: BC Decker, Inc; 1998:367-392.
46. 3. Am J Ind Med. 1996;30:16-25.
47. Rosenman K, Hertzberg V, Rice C, et al. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ Health Perspect. 2005;113:1366-1372.
48. Markham TN. Screening for chronic beryllium disease using beryllium specific lymphocyte proliferation testing. Int Arch Occup Environ Health. 1996;68:405-407.
49. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med. 2004;46:453-462.
50. Stange AW, Furman FJ, Hilmas DE. Rocky flats beryllium health surveillance. Environ Health Perspect. 1996;104(suppl 5):981-986.
51. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry: blood lymphocyte test performance and exposure-disease relations. J Occup Med. 1993;35:267-274.
52. Henneberger PK, Cumro D, Deubner DD, Kent MS, McCawley M, Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001;74:167-176.
53. Deubner DC, Goodman M, Iannuzzi J. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hyg. 2001;16:521-526.
54. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med. 2001;43:231-237.
55. Kreiss K, Mroz MM, Zhen B, Wiederman H, Barna B. Risks of beryllium disease related to work processes at a metal, alloy and oxide production plant. Occup Environ Med. 1997;54:605-612.
56. Bobka CA, Stewart LA, Engelken GJ, Golitz LE, Newman LS. Comparison of in vivo and in vitro measures of beryllium sensitization. J Occup Environ Med. 1997;39:540-547.
57. Schuler CR, Kent MS, Deubner D, et al. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med. 2005;47:195-205.
58. Viet SM, Torma-Krajewski J, Rogers J. Chronic beryllium disease and beryllium sensitization at Rocky Flats: a case-control study. Am Ind Hyg Assoc J. 2000;61:244-254.
59. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol. 1991;88:54-60.
60. Stokes RF, Rossman MD. Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med. 1991;33:23-28.
61. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect. 1996;104(suppl 5):953-956.
62. H1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol. 2005;115:1036-1042.
63. Welch L, Ringen K, Bingham E, et al. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med. 2004;46:207-218.
64. Curtis GH. Cutaneous hypersensitivity due to beryllium: a study of thirteen cases. AMA Arch Dermatol Syphilol. 1951;64:470-482.
65. Beryllium Lymphocyte Proliferation Testing (BeLPT) (DOE-SPEC-1142-2001). Washington, DC: US Department of Energy; 2001.
66. Kreiss K, Miller F, Newman LS, Ojo-Amaize EA, Rossman MD, Saltini C. Chronic beryllium disease - from the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol. 1994;71:123-129.
67. Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. J Clin Invest. 2002;110:1473-1482.
68. Frome EL, Newman LS, Cragle DL, Colyer SP, Wambach PF. Identification of an abnormal beryllium lymphocyte proliferation test. Toxicology. 2003;183:39-56.
69. Yoshida T, Shima S, Nagaoka K, et al. A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Ind Health. 1997;35:374-379.
70. Kolanz ME. Introduction to beryllium: uses, regulatory history, and disease. Appl Occup Environ Hyg. 2001;16:559-567.
71. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research: getting better but still not good. JAMA. 1995;274:645-651.
72. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. Can Med Assoc J. 1986;134:587-594.
73. Gaensler EA, Verstraeten JM, Weil WB, et al. Respiratory pathophysiology in chronic beryllium disease; review of thirty cases with some observations after long-term steroid therapy. AMA Arch Ind Health. 1959;19:132-145.
74. Newman LS, Maier LA. Beryllium disease. In: Schwarz MI, King TE Jr, eds. Interstitial Lung Disease. Hamilton: BC Decker Inc; 2003:435-451.
75. Barton MB, Moore S, Polk S, Shtatland E, Elmore JG, Fletcher SW. Increased patient concern after false-positive mammograms. Clinician documentation and subsequent ambulatory visits. J Gen Intern Med. 2001;16:150-156.
76. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:347-360.
77. Mossey JM. Psychosocial consequences of labeling in hypertension. Clin Invest Med. 1981;4:201-207.
78. Lefebvre RC, Hursey KG, Carleton RA. Labeling of participants in high blood pressure screening programs: implications for blood cholesterol screening. Arch Intern Med. 1988;148:1993-1997.
79. Ford ME, Havstad SL, Demers R, Johnson CC. Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. Cancer Epidemiol Biomarkers Prev. 2005;14:190-194.
80. Billings PR. Genetic nondiscrimination. Nat Genet. 2005;37:559-560.
81. Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet. 1992;50:476-482.
82. Marshall E. Beryllium screening raises ethical issues. Science. 1999;285:178-179.
83. US Department of Energy. Chronic beryllium disease prevention program; final rule. Fed Reg. 1999;64:68854-68914.
84. Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect. 1996;104(suppl 5):945-947.
85. Hardy HL. Beryllium poisoning - lessons in control of man-made disease. N Engl J Med. 1965;273:1188-1199.
86. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Ind Hyg Occup Med. 1951;4:123-151.
87. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993;262:242-244.
88. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001;18:477-684.
89. Maier LA, Kittle LA, Mroz MM, Newman LS. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med. 2003;43:592-601.
90. Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001;100:4-14.
91. + T cells in blood determines proliferative response. J Clin Invest. 2005;115:2886-2893.
92. Occupational Safety and Health Administration. Hazard Information Bulletin: preventing adverse health effects from exposure to beryllium on the job. Washington, DC: US Department of Labor; 1999. Available at: www.osha.gov/dts/hib/hib_data/hib19990902.html. Accessed February 2006.
93. Beryllium Lymphocyte Proliferation Test. Denver: National Jewish Medical and Research Center; 2006. Available at: http://www.njc.org/disease-info/ diseases/occ-med/beryllium/about/test/belpt.aspx. Accessed February 2006.